MA55467A - Utilisations thérapeutiques de dulaglutide - Google Patents

Utilisations thérapeutiques de dulaglutide

Info

Publication number
MA55467A
MA55467A MA055467A MA55467A MA55467A MA 55467 A MA55467 A MA 55467A MA 055467 A MA055467 A MA 055467A MA 55467 A MA55467 A MA 55467A MA 55467 A MA55467 A MA 55467A
Authority
MA
Morocco
Prior art keywords
dulaglutide
therapeutic uses
therapeutic
Prior art date
Application number
MA055467A
Other languages
English (en)
Inventor
Jeffrey S Riesmeyer
David Bradley Woodward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA55467A publication Critical patent/MA55467A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055467A 2019-04-05 2019-11-04 Utilisations thérapeutiques de dulaglutide MA55467A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962829717P 2019-04-05 2019-04-05

Publications (1)

Publication Number Publication Date
MA55467A true MA55467A (fr) 2022-02-09

Family

ID=68732046

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055467A MA55467A (fr) 2019-04-05 2019-11-04 Utilisations thérapeutiques de dulaglutide

Country Status (15)

Country Link
US (2) US11890325B2 (fr)
EP (1) EP3946428A1 (fr)
KR (2) KR20210134713A (fr)
CN (2) CN113631181A (fr)
AU (2) AU2019439626B2 (fr)
BR (1) BR112021017315A2 (fr)
CA (2) CA3056663C (fr)
EA (1) EA202192296A1 (fr)
IL (1) IL285765A (fr)
MA (1) MA55467A (fr)
MX (1) MX2021012177A (fr)
SG (1) SG11202109892UA (fr)
TW (2) TWI804692B (fr)
WO (1) WO2020204998A1 (fr)
ZA (1) ZA202106250B (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2263197A (en) 1996-02-06 1997-08-28 Eli Lilly And Company Diabetes therapy
HU229108B1 (en) 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
SI1355942T1 (sl) 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
EP2168982A1 (fr) 2004-12-22 2010-03-31 Eli Lilly & Company Formules de protéine fusion analogue GLP-1
CN101730523A (zh) 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
EP2566469B1 (fr) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Thérapie combinée
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
WO2015013762A1 (fr) 2013-07-29 2015-02-05 Sg Ventures Pty Limited Pigments métalliques et procédé de revêtement d'un substrat métallique
MA43684A (fr) 2016-03-04 2018-11-28 Novo Nordisk As Liraglutide utilisé dans le traitement de maladies rénales
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
LT3275438T (lt) * 2016-07-29 2021-03-25 Kowa Company, Ltd. Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką
ES2963464T3 (es) 2017-06-01 2024-03-27 Lilly Co Eli Dulaglutida para el tratamiento de la enfermedad renal crónica

Also Published As

Publication number Publication date
BR112021017315A2 (pt) 2021-11-16
EP3946428A1 (fr) 2022-02-09
CN113631181A (zh) 2021-11-09
TW202103729A (zh) 2021-02-01
AU2019439626B2 (en) 2022-10-13
CA3177693A1 (fr) 2020-10-05
KR20210134713A (ko) 2021-11-10
ZA202106250B (en) 2023-04-26
TW202400213A (zh) 2024-01-01
KR20230132627A (ko) 2023-09-15
CA3056663A1 (fr) 2020-10-05
US11890325B2 (en) 2024-02-06
TWI804692B (zh) 2023-06-11
AU2022291679A1 (en) 2023-02-02
CN114732897A (zh) 2022-07-12
IL285765A (en) 2021-10-31
AU2019439626A1 (en) 2021-09-16
US20240139287A1 (en) 2024-05-02
EA202192296A1 (ru) 2022-01-21
US20220202908A1 (en) 2022-06-30
SG11202109892UA (en) 2021-10-28
WO2020204998A1 (fr) 2020-10-08
CA3056663C (fr) 2022-10-18
MX2021012177A (es) 2021-11-04

Similar Documents

Publication Publication Date Title
MD3209309T2 (ro) Compoziții care conțin tulpini bacteriene
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
BR112017005002A2 (pt) macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer.
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
DK3740504T3 (da) CD70 kombinationsterapi
GB201804514D0 (en) Treatment of pyroptosis
MA47820A (fr) Traitement de la glycogénose de type iii
MA43270A (fr) Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
JP1662410S (ja) 患者インターフェース
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
JP1734548S (ja) 医療用支柱アッセンブリ
DK3585808T3 (da) Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
DK3262411T3 (da) Antibody-mediated neutralization of marburg virus
GB201804515D0 (en) Treatment of necroptosis
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
GB201805100D0 (en) Treatment of sarcopenic diseases
MA55467A (fr) Utilisations thérapeutiques de dulaglutide
DK4003533T3 (da) Fremgangsmåder til behandling af multifokal cancer
DE112019004134A5 (de) Tampon
ES1217330Y (es) Muñequera de seguridad
DK4009942T3 (da) Forbindelse til kombinationsbehandling
UA41274S (uk) Масажер